context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 6.6 | monetaryItemType | text: <entity> 6.6 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:PaymentsOfDebtExtinguishmentCosts |
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 266 | monetaryItemType | text: <entity> 266 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:GainsLossesOnExtinguishmentOfDebt |
Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. </context> | us-gaap:RepaymentsOfNotesPayable |
Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. </context> | us-gaap:RepaymentsOfNotesPayable |
Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. | text | 4.8 | monetaryItemType | text: <entity> 4.8 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. </context> | us-gaap:RepaymentsOfNotesPayable |
Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. </context> | us-gaap:InterestPaidNet |
Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. </context> | us-gaap:InterestPaidNet |
Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 2.9 billion in 2024, $ 3.9 billion in 2023 and $ 4.8 billion in 2022. Interest payments were $ 1.8 billion in 2024, $ 1.2 billion in 2023 and $ 1.4 billion in 2022. </context> | us-gaap:InterestPaidNet |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 4.2 | monetaryItemType | text: <entity> 4.2 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 2.1 | monetaryItemType | text: <entity> 2.1 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:InterestExpenseLongTermDebt |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:InterestExpenseLongTermDebt |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:InterestExpenseLongTermDebt |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 1.8 billion in 2025; $ 3.5 billion in 2026; $ 3.0 billion in 2027; $ 1.5 billion in 2028; and $ 4.2 billion in 2029. Interest payments related to long-term debt for each of the next five years are as follows: $ 2.1 billion in 2025; $ 2.0 billion in 2026; $ 1.8 billion in 2027; $ 1.7 billion in 2028; and $ 1.7 billion in 2029. </context> | us-gaap:InterestExpenseLongTermDebt |
As of December 31, 2024, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2029, extendable annually by one year with the consent of the lenders. In January 2025, BMS extended the credit facility to January 2030. In February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility, which expired in January 2025. The facilities provide for customary terms and conditions with no financial covenants and are used to provide backup liquidity for our commercial paper borrowings. No borrowings were outstanding under the revolving credit facilities as of December 31, 2024 or 2023. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2029, extendable annually by one year with the consent of the lenders. In January 2025, BMS extended the credit facility to January 2030. In February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility, which expired in January 2025. The facilities provide for customary terms and conditions with no financial covenants and are used to provide backup liquidity for our commercial paper borrowings. No borrowings were outstanding under the revolving credit facilities as of December 31, 2024 or 2023. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
As of December 31, 2024, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2029, extendable annually by one year with the consent of the lenders. In January 2025, BMS extended the credit facility to January 2030. In February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility, which expired in January 2025. The facilities provide for customary terms and conditions with no financial covenants and are used to provide backup liquidity for our commercial paper borrowings. No borrowings were outstanding under the revolving credit facilities as of December 31, 2024 or 2023. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2029, extendable annually by one year with the consent of the lenders. In January 2025, BMS extended the credit facility to January 2030. In February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility, which expired in January 2025. The facilities provide for customary terms and conditions with no financial covenants and are used to provide backup liquidity for our commercial paper borrowings. No borrowings were outstanding under the revolving credit facilities as of December 31, 2024 or 2023. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
(a) Includes provision for expected credit loss of $ 41 million in 2024, $ 14 million in 2023 and $ 7 million in 2022. | text | 41 | monetaryItemType | text: <entity> 41 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes provision for expected credit loss of $ 41 million in 2024, $ 14 million in 2023 and $ 7 million in 2022. </context> | us-gaap:ProvisionForDoubtfulAccounts |
(a) Includes provision for expected credit loss of $ 41 million in 2024, $ 14 million in 2023 and $ 7 million in 2022. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes provision for expected credit loss of $ 41 million in 2024, $ 14 million in 2023 and $ 7 million in 2022. </context> | us-gaap:ProvisionForDoubtfulAccounts |
(a) Includes provision for expected credit loss of $ 41 million in 2024, $ 14 million in 2023 and $ 7 million in 2022. | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes provision for expected credit loss of $ 41 million in 2024, $ 14 million in 2023 and $ 7 million in 2022. </context> | us-gaap:ProvisionForDoubtfulAccounts |
Depreciation expense was $ 651 million in 2024, $ 611 million in 2023 and $ 587 million in 2022. | text | 651 | monetaryItemType | text: <entity> 651 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 651 million in 2024, $ 611 million in 2023 and $ 587 million in 2022. </context> | us-gaap:Depreciation |
Depreciation expense was $ 651 million in 2024, $ 611 million in 2023 and $ 587 million in 2022. | text | 611 | monetaryItemType | text: <entity> 611 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 651 million in 2024, $ 611 million in 2023 and $ 587 million in 2022. </context> | us-gaap:Depreciation |
Depreciation expense was $ 651 million in 2024, $ 611 million in 2023 and $ 587 million in 2022. | text | 587 | monetaryItemType | text: <entity> 587 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 651 million in 2024, $ 611 million in 2023 and $ 587 million in 2022. </context> | us-gaap:Depreciation |
Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. | text | 22 | monetaryItemType | text: <entity> 22 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. </context> | us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability |
Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. | text | 240 | monetaryItemType | text: <entity> 240 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. </context> | us-gaap:OperatingLeasePayments |
Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. | text | 195 | monetaryItemType | text: <entity> 195 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. </context> | us-gaap:OperatingLeasePayments |
Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. | text | 203 | monetaryItemType | text: <entity> 203 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for operating lease obligations were $ 22 million in 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $ 240 million in 2024, $ 195 million in 2023 and $ 203 million in 2022. </context> | us-gaap:OperatingLeasePayments |
Undiscounted lease obligations for operating leases not yet commenced were approximately $ 600 million as of December 31, 2024 and primarily relate to a research and development facility that is being constructed by the lessor. | text | 600 | monetaryItemType | text: <entity> 600 </entity> <entity type> monetaryItemType </entity type> <context> Undiscounted lease obligations for operating leases not yet commenced were approximately $ 600 million as of December 31, 2024 and primarily relate to a research and development facility that is being constructed by the lessor. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount |
In 2023, BMS agreed to pay $ 400 million to the former shareholders of Impact Biomedicines to extinguish all remaining contingent milestone obligations, which was recorded to Acquired marketed product rights for | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS agreed to pay $ 400 million to the former shareholders of Impact Biomedicines to extinguish all remaining contingent milestone obligations, which was recorded to Acquired marketed product rights for </context> | us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities |
in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. | text | 511 | monetaryItemType | text: <entity> 511 </entity> <entity type> monetaryItemType </entity type> <context> in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. </context> | us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease |
in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. </context> | us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 9.0 | monetaryItemType | text: <entity> 9.0 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 9.2 | monetaryItemType | text: <entity> 9.2 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 9.7 | monetaryItemType | text: <entity> 9.7 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour |
Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.0 billion in 2024, $ 9.2 billion in 2023 and $ 9.7 billion in 2022. Future annual amortization expense of Other intangible assets is expected to be approximately $ 3.5 billion in 2025, $ 1.9 billion in 2026, $ 1.9 billion in 2027, $ 1.8 billion in 2028 and $ 1.7 billion in 2029. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive |
Other intangible asset impairments were $ 2.9 billion in 2024, $ 136 million in 2023 and $ 101 million in 2022. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> Other intangible asset impairments were $ 2.9 billion in 2024, $ 136 million in 2023 and $ 101 million in 2022. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
Other intangible asset impairments were $ 2.9 billion in 2024, $ 136 million in 2023 and $ 101 million in 2022. | text | 136 | monetaryItemType | text: <entity> 136 </entity> <entity type> monetaryItemType </entity type> <context> Other intangible asset impairments were $ 2.9 billion in 2024, $ 136 million in 2023 and $ 101 million in 2022. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
Other intangible asset impairments were $ 2.9 billion in 2024, $ 136 million in 2023 and $ 101 million in 2022. | text | 101 | monetaryItemType | text: <entity> 101 </entity> <entity type> monetaryItemType </entity type> <context> Other intangible asset impairments were $ 2.9 billion in 2024, $ 136 million in 2023 and $ 101 million in 2022. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
During the three months ended December 31, 2024, a $ 1.4 billion impairment charge for | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> During the three months ended December 31, 2024, a $ 1.4 billion impairment charge for </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
During the three months ended December 31, 2024, a $ 122 million impairment charge for | text | 122 | monetaryItemType | text: <entity> 122 </entity> <entity type> monetaryItemType </entity type> <context> During the three months ended December 31, 2024, a $ 122 million impairment charge for </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
During the three months ended June 30, 2024, a $ 280 million impairment charge was recorded in Cost of products goods sold resulting from lower revised cash flow projections for | text | 280 | monetaryItemType | text: <entity> 280 </entity> <entity type> monetaryItemType </entity type> <context> During the three months ended June 30, 2024, a $ 280 million impairment charge was recorded in Cost of products goods sold resulting from lower revised cash flow projections for </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
During the three months ended December 31, 2024, a $ 390 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of pipeline opportunities. The compound was being studied as a potential treatment for immunologic diseases and was acquired in the acquisition of Celgene. The IPRD impairment charge represented a full write-down of the asset. | text | 390 | monetaryItemType | text: <entity> 390 </entity> <entity type> monetaryItemType </entity type> <context> During the three months ended December 31, 2024, a $ 390 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of pipeline opportunities. The compound was being studied as a potential treatment for immunologic diseases and was acquired in the acquisition of Celgene. The IPRD impairment charge represented a full write-down of the asset. </context> | us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill |
(a) Cash dividends declared per common share were $ 2.42 in 2024, $ 2.31 in 2023 and $ 2.19 in 2022. | text | 2.42 | perShareItemType | text: <entity> 2.42 </entity> <entity type> perShareItemType </entity type> <context> (a) Cash dividends declared per common share were $ 2.42 in 2024, $ 2.31 in 2023 and $ 2.19 in 2022. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
(a) Cash dividends declared per common share were $ 2.42 in 2024, $ 2.31 in 2023 and $ 2.19 in 2022. | text | 2.31 | perShareItemType | text: <entity> 2.31 </entity> <entity type> perShareItemType </entity type> <context> (a) Cash dividends declared per common share were $ 2.42 in 2024, $ 2.31 in 2023 and $ 2.19 in 2022. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
(a) Cash dividends declared per common share were $ 2.42 in 2024, $ 2.31 in 2023 and $ 2.19 in 2022. | text | 2.19 | perShareItemType | text: <entity> 2.19 </entity> <entity type> perShareItemType </entity type> <context> (a) Cash dividends declared per common share were $ 2.42 in 2024, $ 2.31 in 2023 and $ 2.19 in 2022. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares, effected in the open market or through privately negotiated transactions in compliance with Rule 10b-18 under the Exchange Act, including through Rule 10b5-1 trading plans. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method and are generally funded by cash on hand. In December 2023, the Board of Directors approved an increase of $ 3.0 billion to the share repurchase authorization for BMS's common stock. The remaining share repurchase capacity under the BMS share repurchase program was $ 5.0 billion as of December 31, 2024. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares, effected in the open market or through privately negotiated transactions in compliance with Rule 10b-18 under the Exchange Act, including through Rule 10b5-1 trading plans. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method and are generally funded by cash on hand. In December 2023, the Board of Directors approved an increase of $ 3.0 billion to the share repurchase authorization for BMS's common stock. The remaining share repurchase capacity under the BMS share repurchase program was $ 5.0 billion as of December 31, 2024. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 70 | sharesItemType | text: <entity> 70 </entity> <entity type> sharesItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 4.0 | monetaryItemType | text: <entity> 4.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 17 | sharesItemType | text: <entity> 17 </entity> <entity type> sharesItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 69 | sharesItemType | text: <entity> 69 </entity> <entity type> sharesItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 40 | sharesItemType | text: <entity> 40 </entity> <entity type> sharesItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
(a) Includes net investment hedge gains of $ 210 million and $ 144 million as of December 31, 2024 and December 31, 2023, respectively. | text | 210 | monetaryItemType | text: <entity> 210 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes net investment hedge gains of $ 210 million and $ 144 million as of December 31, 2024 and December 31, 2023, respectively. </context> | us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax |
(a) Includes net investment hedge gains of $ 210 million and $ 144 million as of December 31, 2024 and December 31, 2023, respectively. | text | 144 | monetaryItemType | text: <entity> 144 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes net investment hedge gains of $ 210 million and $ 144 million as of December 31, 2024 and December 31, 2023, respectively. </context> | us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax |
The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. | text | 27 | monetaryItemType | text: <entity> 27 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. | text | 119 | monetaryItemType | text: <entity> 119 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 15 million, $ 11 million, and $ 27 million during the years ended December 31, 2024, 2023 and 2022, respectively. In addition, pension settlement charges of $ 119 million were recorded in 2024 in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan. </context> | us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 |
The accumulated benefit obligation for defined benefit pension plans was $ 1.9 billion and $ 2.2 billion at December 31, 2024 and 2023, respectively. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> The accumulated benefit obligation for defined benefit pension plans was $ 1.9 billion and $ 2.2 billion at December 31, 2024 and 2023, respectively. </context> | us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation |
The accumulated benefit obligation for defined benefit pension plans was $ 1.9 billion and $ 2.2 billion at December 31, 2024 and 2023, respectively. | text | 2.2 | monetaryItemType | text: <entity> 2.2 </entity> <entity type> monetaryItemType </entity type> <context> The accumulated benefit obligation for defined benefit pension plans was $ 1.9 billion and $ 2.2 billion at December 31, 2024 and 2023, respectively. </context> | us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. | text | 160 | monetaryItemType | text: <entity> 160 </entity> <entity type> monetaryItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. </context> | us-gaap:DefinedBenefitPlanBenefitObligation |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. | text | 183 | monetaryItemType | text: <entity> 183 </entity> <entity type> monetaryItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. </context> | us-gaap:DefinedBenefitPlanBenefitObligation |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. | text | 5.4 | percentItemType | text: <entity> 5.4 </entity> <entity type> percentItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. </context> | us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. | text | 4.8 | percentItemType | text: <entity> 4.8 </entity> <entity type> percentItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 160 million and $ 183 million at December 31, 2024 and 2023, respectively. The weighted-average discount rate used to determine benefit obligations was 5.4 % and 4.8 % at December 31, 2024 and 2023, respectively. The net periodic benefit costs were not material. </context> | us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate |
The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2024 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 35 %) and other investments ( 44 %). | text | 21 | percentItemType | text: <entity> 21 </entity> <entity type> percentItemType </entity type> <context> The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2024 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 35 %) and other investments ( 44 %). </context> | us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations |
The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2024 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 35 %) and other investments ( 44 %). | text | 35 | percentItemType | text: <entity> 35 </entity> <entity type> percentItemType </entity type> <context> The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2024 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 35 %) and other investments ( 44 %). </context> | us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations |
The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2024 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 35 %) and other investments ( 44 %). | text | 44 | percentItemType | text: <entity> 44 </entity> <entity type> percentItemType </entity type> <context> The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2024 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 35 %) and other investments ( 44 %). </context> | us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations |
The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 395 million in 2024, $ 380 million in 2023 and $ 360 million in 2022. | text | 395 | monetaryItemType | text: <entity> 395 </entity> <entity type> monetaryItemType </entity type> <context> The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 395 million in 2024, $ 380 million in 2023 and $ 360 million in 2022. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 395 million in 2024, $ 380 million in 2023 and $ 360 million in 2022. | text | 380 | monetaryItemType | text: <entity> 380 </entity> <entity type> monetaryItemType </entity type> <context> The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 395 million in 2024, $ 380 million in 2023 and $ 360 million in 2022. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 395 million in 2024, $ 380 million in 2023 and $ 360 million in 2022. | text | 360 | monetaryItemType | text: <entity> 360 </entity> <entity type> monetaryItemType </entity type> <context> The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 395 million in 2024, $ 380 million in 2023 and $ 360 million in 2022. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2024, 64 million shares were available for award and 38 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. | text | 85 | sharesItemType | text: <entity> 85 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2024, 64 million shares were available for award and 38 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2024, 64 million shares were available for award and 38 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. | text | 64 | sharesItemType | text: <entity> 64 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2024, 64 million shares were available for award and 38 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2024, 64 million shares were available for award and 38 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. | text | 38 | sharesItemType | text: <entity> 38 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2024, 64 million shares were available for award and 38 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
(a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $( 27 ) million in 2024, $ 19 million in 2023 and $ 74 million in 2022. | text | 27 | monetaryItemType | text: <entity> 27 </entity> <entity type> monetaryItemType </entity type> <context> (a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $( 27 ) million in 2024, $ 19 million in 2023 and $ 74 million in 2022. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
(a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $( 27 ) million in 2024, $ 19 million in 2023 and $ 74 million in 2022. | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> (a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $( 27 ) million in 2024, $ 19 million in 2023 and $ 74 million in 2022. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
(a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $( 27 ) million in 2024, $ 19 million in 2023 and $ 74 million in 2022. | text | 74 | monetaryItemType | text: <entity> 74 </entity> <entity type> monetaryItemType </entity type> <context> (a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $( 27 ) million in 2024, $ 19 million in 2023 and $ 74 million in 2022. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the closing stock price of $ 56.56 on December 31, 2024, which was the last trading day of 2024. | text | 56.56 | perShareItemType | text: <entity> 56.56 </entity> <entity type> perShareItemType </entity type> <context> The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the closing stock price of $ 56.56 on December 31, 2024, which was the last trading day of 2024. </context> | us-gaap:SharePrice |
*. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. | text | 834 | monetaryItemType | text: <entity> 834 </entity> <entity type> monetaryItemType </entity type> <context> *. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. </context> | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
*. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. | text | 417 | monetaryItemType | text: <entity> 417 </entity> <entity type> monetaryItemType </entity type> <context> *. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. </context> | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
*. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. | text | 916 | monetaryItemType | text: <entity> 916 </entity> <entity type> monetaryItemType </entity type> <context> *. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. </context> | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
*. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. | text | 458 | monetaryItemType | text: <entity> 458 </entity> <entity type> monetaryItemType </entity type> <context> *. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $ 834 million, with $ 417 million attributed to BMS. In March 2023, the Hawaii Supreme Court reversed in part and affirmed in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. Following a new trial, in May 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $ 916 million, with $ 458 million attributed to BMS. Sanofi and BMS have appealed the decision. </context> | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
) before a contractual milestone date, thereby allegedly avoiding a $ 6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the alleged successor trustee. The plaintiff sought damages in an amount to be determined at trial and other relief, including interest and attorneys’ fees. BMS disputes the allegations. BMS filed a motion to dismiss the alleged successor trustee’s complaint for failure to state a claim upon which relief can be granted, which was denied in June 2022. In February 2024, BMS filed a motion to dismiss the complaint for lack of subject matter jurisdiction. In September 2024, the court granted BMS’s motion and dismissed the lawsuit for lack of subject matter jurisdiction without prejudice to the refiling of a new lawsuit by a properly appointed trustee. The plaintiff has appealed, and BMS has cross-appealed from the denial of its first motion to dismiss. | text | 6.4 | monetaryItemType | text: <entity> 6.4 </entity> <entity type> monetaryItemType </entity type> <context> ) before a contractual milestone date, thereby allegedly avoiding a $ 6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the alleged successor trustee. The plaintiff sought damages in an amount to be determined at trial and other relief, including interest and attorneys’ fees. BMS disputes the allegations. BMS filed a motion to dismiss the alleged successor trustee’s complaint for failure to state a claim upon which relief can be granted, which was denied in June 2022. In February 2024, BMS filed a motion to dismiss the complaint for lack of subject matter jurisdiction. In September 2024, the court granted BMS’s motion and dismissed the lawsuit for lack of subject matter jurisdiction without prejudice to the refiling of a new lawsuit by a properly appointed trustee. The plaintiff has appealed, and BMS has cross-appealed from the denial of its first motion to dismiss. </context> | us-gaap:ContractualObligation |
Stockholders are entitled to receive, when and if declared by our Board of Directors from time to time, dividends and other distributions in cash, stock or property from our assets or funds legally and contractually available for such purposes. In February 2024, our Board of Directors approved a dividend of $0.13 per share of common stock, which was paid on March 29 to stockholders of record as of March 15. In May 2024, August 2024 and December 2024, our Board of Directors approved dividends of $0.14 per share of common stock, which were paid on June 28, September 30 and December 31, 2024 to stockholders of record as of June 14, September 13 and December 16, 2024, respectively. We made total dividend payments of $ 64.7 million during 2024. Our liability related to dividends on common stock was $ 2.5 million and $ 1.3 million as of December 31, 2024 and 2023, respectively. | text | 64.7 | monetaryItemType | text: <entity> 64.7 </entity> <entity type> monetaryItemType </entity type> <context> Stockholders are entitled to receive, when and if declared by our Board of Directors from time to time, dividends and other distributions in cash, stock or property from our assets or funds legally and contractually available for such purposes. In February 2024, our Board of Directors approved a dividend of $0.13 per share of common stock, which was paid on March 29 to stockholders of record as of March 15. In May 2024, August 2024 and December 2024, our Board of Directors approved dividends of $0.14 per share of common stock, which were paid on June 28, September 30 and December 31, 2024 to stockholders of record as of June 14, September 13 and December 16, 2024, respectively. We made total dividend payments of $ 64.7 million during 2024. Our liability related to dividends on common stock was $ 2.5 million and $ 1.3 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:PaymentsOfDividendsCommonStock |
Stockholders are entitled to receive, when and if declared by our Board of Directors from time to time, dividends and other distributions in cash, stock or property from our assets or funds legally and contractually available for such purposes. In February 2024, our Board of Directors approved a dividend of $0.13 per share of common stock, which was paid on March 29 to stockholders of record as of March 15. In May 2024, August 2024 and December 2024, our Board of Directors approved dividends of $0.14 per share of common stock, which were paid on June 28, September 30 and December 31, 2024 to stockholders of record as of June 14, September 13 and December 16, 2024, respectively. We made total dividend payments of $ 64.7 million during 2024. Our liability related to dividends on common stock was $ 2.5 million and $ 1.3 million as of December 31, 2024 and 2023, respectively. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> Stockholders are entitled to receive, when and if declared by our Board of Directors from time to time, dividends and other distributions in cash, stock or property from our assets or funds legally and contractually available for such purposes. In February 2024, our Board of Directors approved a dividend of $0.13 per share of common stock, which was paid on March 29 to stockholders of record as of March 15. In May 2024, August 2024 and December 2024, our Board of Directors approved dividends of $0.14 per share of common stock, which were paid on June 28, September 30 and December 31, 2024 to stockholders of record as of June 14, September 13 and December 16, 2024, respectively. We made total dividend payments of $ 64.7 million during 2024. Our liability related to dividends on common stock was $ 2.5 million and $ 1.3 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:DividendsPayableCurrentAndNoncurrent |
Stockholders are entitled to receive, when and if declared by our Board of Directors from time to time, dividends and other distributions in cash, stock or property from our assets or funds legally and contractually available for such purposes. In February 2024, our Board of Directors approved a dividend of $0.13 per share of common stock, which was paid on March 29 to stockholders of record as of March 15. In May 2024, August 2024 and December 2024, our Board of Directors approved dividends of $0.14 per share of common stock, which were paid on June 28, September 30 and December 31, 2024 to stockholders of record as of June 14, September 13 and December 16, 2024, respectively. We made total dividend payments of $ 64.7 million during 2024. Our liability related to dividends on common stock was $ 2.5 million and $ 1.3 million as of December 31, 2024 and 2023, respectively. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> Stockholders are entitled to receive, when and if declared by our Board of Directors from time to time, dividends and other distributions in cash, stock or property from our assets or funds legally and contractually available for such purposes. In February 2024, our Board of Directors approved a dividend of $0.13 per share of common stock, which was paid on March 29 to stockholders of record as of March 15. In May 2024, August 2024 and December 2024, our Board of Directors approved dividends of $0.14 per share of common stock, which were paid on June 28, September 30 and December 31, 2024 to stockholders of record as of June 14, September 13 and December 16, 2024, respectively. We made total dividend payments of $ 64.7 million during 2024. Our liability related to dividends on common stock was $ 2.5 million and $ 1.3 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:DividendsPayableCurrentAndNoncurrent |
We had an outstanding aggregate balance of $ 1,807.7 million under the Term Loan as of December 31, 2024. Under our Term Loan, we pay interest at an annual rate equal to SOFR plus 2.25%, with a 0.75% SOFR floor. Accordingly, we have been and continue to be subject to interest rate fluctuations. Our Cap began in December 2021, which manages our exposure to interest rate movements on a notional amount of $1.0 billion of our Term Loan. In 2024, the Cap provided the right for us to receive payment from the counterparty if one-month SOFR exceeded 1.436%. (See | text | 1807.7 | monetaryItemType | text: <entity> 1807.7 </entity> <entity type> monetaryItemType </entity type> <context> We had an outstanding aggregate balance of $ 1,807.7 million under the Term Loan as of December 31, 2024. Under our Term Loan, we pay interest at an annual rate equal to SOFR plus 2.25%, with a 0.75% SOFR floor. Accordingly, we have been and continue to be subject to interest rate fluctuations. Our Cap began in December 2021, which manages our exposure to interest rate movements on a notional amount of $1.0 billion of our Term Loan. In 2024, the Cap provided the right for us to receive payment from the counterparty if one-month SOFR exceeded 1.436%. (See </context> | us-gaap:DebtInstrumentCarryingAmount |
The Company’s raw materials balance includes $ 21.2 million and $ 32.2 million at December 31, 2024 and December 31, 2023, respectively, of inventory held on consignment at third-party manufacturers. | text | 21.2 | monetaryItemType | text: <entity> 21.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s raw materials balance includes $ 21.2 million and $ 32.2 million at December 31, 2024 and December 31, 2023, respectively, of inventory held on consignment at third-party manufacturers. </context> | us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment |
The Company’s raw materials balance includes $ 21.2 million and $ 32.2 million at December 31, 2024 and December 31, 2023, respectively, of inventory held on consignment at third-party manufacturers. | text | 32.2 | monetaryItemType | text: <entity> 32.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s raw materials balance includes $ 21.2 million and $ 32.2 million at December 31, 2024 and December 31, 2023, respectively, of inventory held on consignment at third-party manufacturers. </context> | us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment |
During the fourth quarter of 2023, the Company updated its estimate of the satellites’ remaining useful lives based on the health of the constellation and related engineering data. As a result, the estimated useful lives of the satellites were extended by five years, from 12.5 years to 17.5 years. The impact of this change for the year ended December 31, 2023 was a decrease in depreciation expense of approximately $ 27.8 million and a decrease in hosted payload and other service revenue of approximately $ 2.3 million. For the year ended December 31, 2023, the impact of the change in useful lives of the satellites resulted in an increase in basic and diluted net income per share of $ 0.21 and $ 0.20 , respectively. | text | 0.21 | perShareItemType | text: <entity> 0.21 </entity> <entity type> perShareItemType </entity type> <context> During the fourth quarter of 2023, the Company updated its estimate of the satellites’ remaining useful lives based on the health of the constellation and related engineering data. As a result, the estimated useful lives of the satellites were extended by five years, from 12.5 years to 17.5 years. The impact of this change for the year ended December 31, 2023 was a decrease in depreciation expense of approximately $ 27.8 million and a decrease in hosted payload and other service revenue of approximately $ 2.3 million. For the year ended December 31, 2023, the impact of the change in useful lives of the satellites resulted in an increase in basic and diluted net income per share of $ 0.21 and $ 0.20 , respectively. </context> | us-gaap:BasicEarningsPerShareAdjustmentProForma |
During the fourth quarter of 2023, the Company updated its estimate of the satellites’ remaining useful lives based on the health of the constellation and related engineering data. As a result, the estimated useful lives of the satellites were extended by five years, from 12.5 years to 17.5 years. The impact of this change for the year ended December 31, 2023 was a decrease in depreciation expense of approximately $ 27.8 million and a decrease in hosted payload and other service revenue of approximately $ 2.3 million. For the year ended December 31, 2023, the impact of the change in useful lives of the satellites resulted in an increase in basic and diluted net income per share of $ 0.21 and $ 0.20 , respectively. | text | 0.20 | perShareItemType | text: <entity> 0.20 </entity> <entity type> perShareItemType </entity type> <context> During the fourth quarter of 2023, the Company updated its estimate of the satellites’ remaining useful lives based on the health of the constellation and related engineering data. As a result, the estimated useful lives of the satellites were extended by five years, from 12.5 years to 17.5 years. The impact of this change for the year ended December 31, 2023 was a decrease in depreciation expense of approximately $ 27.8 million and a decrease in hosted payload and other service revenue of approximately $ 2.3 million. For the year ended December 31, 2023, the impact of the change in useful lives of the satellites resulted in an increase in basic and diluted net income per share of $ 0.21 and $ 0.20 , respectively. </context> | us-gaap:EarningsPerShareDilutedProFormaAdjustment |
During the quarter ended June 30, 2023, the Company launched five of its remaining six ground spare satellites. Following completion of successful on-orbit testing of the five launched satellites, the Company has no plans to use, develop or launch the remaining ground spare. As the Company believed the construction-in-progress associated with the remaining ground spare satellite would no longer be used, the Company wrote off the full amount remaining in construction-in-progress for that satellite by recording accelerated depreciation expense of $ 37.5 million, which more than offset the decrease in depreciation expense related to the increase in estimated useful lives of the satellites described above. | text | 37.5 | monetaryItemType | text: <entity> 37.5 </entity> <entity type> monetaryItemType </entity type> <context> During the quarter ended June 30, 2023, the Company launched five of its remaining six ground spare satellites. Following completion of successful on-orbit testing of the five launched satellites, the Company has no plans to use, develop or launch the remaining ground spare. As the Company believed the construction-in-progress associated with the remaining ground spare satellite would no longer be used, the Company wrote off the full amount remaining in construction-in-progress for that satellite by recording accelerated depreciation expense of $ 37.5 million, which more than offset the decrease in depreciation expense related to the increase in estimated useful lives of the satellites described above. </context> | us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf |
Depreciation expense was $ 195.9 million, $ 318.5 million and $ 301.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. See “Property and Equipment” in | text | 195.9 | monetaryItemType | text: <entity> 195.9 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 195.9 million, $ 318.5 million and $ 301.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. See “Property and Equipment” in </context> | us-gaap:Depreciation |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.